[36] The role of loco-regional therapy, in particular with the use of radiofrequency ablation (RFA), in recurrent HCC is still emerging. There is no evidence to support RFA as an alternative to SLT or repeat hepatic resection in patients with recurrent HCC, except in those unsuitable for operative management. Chan et al. reported a single-center retrospective series and demonstrated significantly poorer 5-year overall and disease-free survival outcomes with RFA

compared with SLT or repeat hepatic resection (11% vs 50%, 48%).[44] The role of RFA as neoadjuvant or adjuvant loco-regional therapy in Tyrosine Kinase Inhibitor Library price relation to SLT is also unclear. Certainly for patients with disease exceeding the Milan criteria, RFA may be effective in downstaging the tumor;[45] however, the limited evidence available does not currently support improved disease-free or overall survival in this setting.[46] Synthesis of available observational studies suggests that SLT following primary hepatic resection is a highly applicable treatment option with long-term survival outcomes and acceptable SB203580 low rates of morbidity and mortality. Although no randomized studies between the two treatment strategies currently exist, the results of this review suggest that the tolerance and efficacy of these two treatment strategies may be comparable.

The treatment strategy of primary hepatic resection followed by SLT may present an alternative to upfront liver transplantation with several potential benefits and is a clinical practice strategy that warrants further well-conducted randomized comparison study. “
“MicroRNAs (miRNAs) are small, noncoding dipyridamole RNAs that can act as oncogenes

or tumor suppressors in human cancer. Our previous study showed that miR-125b was a prognostic indicator for patients with hepatocellular carcinoma (HCC), but its functions and exact mechanisms in hepatic carcinogenesis are still unknown. Here we demonstrate that miR-125b suppressed HCC cell growth in vitro and in vivo. Moreover, miR-125b increased p21Cip1/Waf1 expression and arrested cell cycle at G1 to S transition. In addition, miR-125b inhibited HCC cell migration and invasion. Further studies revealed that LIN28B was a downstream target of miR-125b in HCC cells as miR-125b bound directly to the 3′ untranslated region of LIN28B, thus reducing both the messenger RNA and protein levels of LIN28B. Silencing of LIN28B recapitulated the effects of miR-125b overexpression, whereas enforced expression of LIN28B reversed the suppressive effects of miR-125b. Conclusion: These findings indicate that miR-125b exerts tumor-suppressive effects in hepatic carcinogenesis through the suppression of oncogene LIN28B expression and suggest a therapeutic application of miR-125b in HCC.